

# Xi-Ping Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3633790/publications.pdf>

Version: 2024-02-01

95  
papers

16,491  
citations

41344

49  
h-index

36028

97  
g-index

112  
all docs

112  
docs citations

112  
times ranked

23509  
citing authors

#	ARTICLE	IF	CITATIONS
1	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <i>Nature</i> , 2020, 583, 459-468.	27.8	3,542
2	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , 2016, 533, 481-486.	27.8	1,246
3	Structure of the human $\mu$ -opioid receptor in complex with JDTic. <i>Nature</i> , 2012, 485, 327-332.	27.8	797
4	Structure-based discovery of opioid analgesics with reduced side effects. <i>Nature</i> , 2016, 537, 185-190.	27.8	744
5	Automated design of ligands to polypharmacological profiles. <i>Nature</i> , 2012, 492, 215-220.	27.8	698
6	Structural Features for Functional Selectivity at Serotonin Receptors. <i>Science</i> , 2013, 340, 615-619.	12.6	600
7	PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 362-369.	8.2	535
8	Structural Basis for Molecular Recognition at Serotonin Receptors. <i>Science</i> , 2013, 340, 610-614.	12.6	454
9	Molecular control of $\mu$ -opioid receptor signalling. <i>Nature</i> , 2014, 506, 191-196.	27.8	432
10	Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. <i>Nature</i> , 2012, 485, 395-399.	27.8	430
11	Structure of the human smoothed receptor bound to an antitumour agent. <i>Nature</i> , 2013, 497, 338-343.	27.8	415
12	A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior. <i>Neuron</i> , 2015, 86, 936-946.	8.1	320
13	Discovery of $\mu$ -Arrestin-Biased Dopamine D <sub>2</sub> Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18488-18493.	7.1	312
14	Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. <i>Cell</i> , 2018, 172, 55-67.e15.	28.9	299
15	Comprehensive characterization of the Published Kinase Inhibitor Set. <i>Nature Biotechnology</i> , 2016, 34, 95-103.	17.5	289
16	Amisulpride is a potent 5-HT <sub>7</sub> antagonist: relevance for antidepressant actions in vivo. <i>Psychopharmacology</i> , 2009, 205, 119-128.	3.1	240
17	In silico design of novel probes for the atypical opioid receptor MRGPRX2. <i>Nature Chemical Biology</i> , 2017, 13, 529-536.	8.0	230
18	Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. <i>Nature</i> , 2015, 527, 477-483.	27.8	214

#	ARTICLE	IF	CITATIONS
19	Structural basis for Smoothed receptor modulation and chemoresistance to anticancer drugs. Nature Communications, 2014, 5, 4355.	12.8	208
20	Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nature Neuroscience, 2020, 23, 1157-1167.	14.8	187
21	5-HT <sub>2C</sub> Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology. Cell, 2018, 172, 719-730.e14.	28.9	185
22	Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature, 2020, 579, 609-614.	27.8	184
23	D <sub>4</sub> dopamine receptor high-resolution structures enable the discovery of selective agonists. Science, 2017, 358, 381-386.	12.6	176
24	Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors. Cell, 2019, 179, 895-908.e21.	28.9	157
25	Synthon-based ligand discovery in virtual libraries of over 11 billion compounds. Nature, 2022, 601, 452-459.	27.8	153
26	Neurochemical profiles of some novel psychoactive substances. European Journal of Pharmacology, 2013, 700, 147-151.	3.5	150
27	Structural basis of ligand recognition at the human MT <sub>1</sub> melatonin receptor. Nature, 2019, 569, 284-288.	27.8	140
28	Structural insights into the human D <sub>1</sub> and D <sub>2</sub> dopamine receptor signaling complexes. Cell, 2021, 184, 931-942.e18.	28.9	140
29	A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nature Chemical Biology, 2016, 12, 180-187.	8.0	133
30	The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor. PLoS ONE, 2013, 8, e59334.	2.5	132
31	The First Structure-Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs. ACS Chemical Neuroscience, 2015, 6, 476-484.	3.5	128
32	Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine <sub>2B</sub> Receptor Agonists: Implications for Drug Safety Assessment. Molecular Pharmacology, 2009, 76, 710-722.	2.3	125
33	Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds. Nature Chemical Biology, 2016, 12, 559-566.	8.0	124
34	Structures of the $\beta_2$ receptor enable docking for bioactive ligand discovery. Nature, 2021, 600, 759-764.	27.8	113
35	XFEL structures of the human MT <sub>2</sub> melatonin receptor reveal the basis of subtype selectivity. Nature, 2019, 569, 289-292.	27.8	106
36	Structure, function and pharmacology of human itch GPCRs. Nature, 2021, 600, 170-175.	27.8	101

#	ARTICLE	IF	CITATIONS
37	Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 461-476.	5.4	99
38	Photochemical activation of TRPA1 channels in neurons and animals. <i>Nature Chemical Biology</i> , 2013, 9, 257-263.	8.0	97
39	Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 359, 159-170.	2.5	89
40	Novel Molecular Targets of Dezocine and Their Clinical Implications. <i>Anesthesiology</i> , 2014, 120, 714-723.	2.5	77
41	Marine Algal Toxin Azaspiracid Is an Open-State Blocker of hERG Potassium Channels. <i>Chemical Research in Toxicology</i> , 2012, 25, 1975-1984.	3.3	72
42	A Simple Representation of Three-Dimensional Molecular Structure. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7393-7409.	6.4	72
43	Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5749-5759.	6.4	68
44	Identification of Human <i>ether-Å-go-go</i> Related Gene Modulators by Three Screening Platforms in an Academic Drug-Discovery Setting. <i>Assay and Drug Development Technologies</i> , 2010, 8, 727-742.	1.2	67
45	Discovery of $\beta_2$ Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1005-1010.	2.8	65
46	COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. <i>Frontiers in Pharmacology</i> , 2021, 12, 633680.	3.5	64
47	The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy. <i>Neuropsychopharmacology</i> , 2011, 36, 638-651.	5.4	63
48	The activities of drug inactive ingredients on biological targets. <i>Science</i> , 2020, 369, 403-413.	12.6	61
49	Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. <i>Molecular Pharmacology</i> , 2005, 68, 769-778.	2.3	57
50	Structures of the human dopamine D3 receptor-Gi complexes. <i>Molecular Cell</i> , 2021, 81, 1147-1159.e4.	9.7	51
51	Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc. <i>Molecular Pharmacology</i> , 2016, 90, 726-737.	2.3	48
52	Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor. <i>Cell Research</i> , 2021, 31, 593-596.	12.0	48
53	Design, Synthesis, and Biological Characterization of Bivalent 1-Methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole Derivatives as Selective Muscarinic Agonists. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4563-4576.	6.4	47
54	Roles of threonine $\epsilon$ 192 and asparagine $\epsilon$ 382 in agonist and antagonist interactions with M1 muscarinic receptors. <i>British Journal of Pharmacology</i> , 1999, 126, 735-745.	5.4	42

#	ARTICLE	IF	CITATIONS
55	Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3070-3081.	6.4	42
56	Synthesis, Pharmacological Characterization, and Structure-Activity Relationship Studies of Small Molecular Agonists for the Orphan GPR88 Receptor. <i>ACS Chemical Neuroscience</i> , 2014, 5, 576-587.	3.5	41
57	Selectivity and Anti-Parkinson's Potential of Thiadiazolidinone RGS4 Inhibitors. <i>ACS Chemical Neuroscience</i> , 2015, 6, 911-919.	3.5	41
58	Development, Validation, and Use of Quantitative Structure-Activity Relationship Models of 5-Hydroxytryptamine (2B) Receptor Ligands to Identify Novel Receptor Binders and Putative Valvulopathic Compounds among Common Drugs. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7573-7586.	6.4	38
59	Îf1 receptor ligands control a switch between passive and active threat responses. <i>Nature Chemical Biology</i> , 2016, 12, 552-558.	8.0	37
60	An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging "Novel Psychoactive Drugs". <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3411-3415.	2.2	36
61	Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 707-720.	6.4	35
62	Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6830-6845.	6.4	31
63	Zanos et al. reply. <i>Nature</i> , 2017, 546, E4-E5.	27.8	29
64	In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. <i>PLoS ONE</i> , 2016, 11, e0150602.	2.5	28
65	Structure-based discovery of potent and selective melatonin receptor agonists. <i>ELife</i> , 2020, 9, .	6.0	28
66	Selective Î² Opioid Antagonists nor-BNI, GNTI and JD1c Have Low Affinities for Non-Opioid Receptors and Transporters. <i>PLoS ONE</i> , 2013, 8, e70701.	2.5	27
67	Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 578-591.	6.4	26
68	Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin. <i>FASEB Journal</i> , 2017, 31, 2507-2519.	0.5	26
69	A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts. <i>ACS Central Science</i> , 2020, 6, 213-225.	11.3	25
70	Dezocine Alleviates Morphine-Induced Dependence in Rats. <i>Anesthesia and Analgesia</i> , 2019, 128, 1328-1335.	2.2	24
71	hERG Blockade by Iboga Alkaloids. <i>Cardiovascular Toxicology</i> , 2016, 16, 14-22.	2.7	23
72	Designing Functionally Selective Noncatechol Dopamine D <sub>1</sub> Receptor Agonists with Potent In Vivo Antiparkinsonian Activity. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4160-4182.	3.5	21

#	ARTICLE	IF	CITATIONS
73	Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. <i>Pharmaceutica Acta Helvetiae</i> , 2000, 74, 135-140.	1.2	19
74	Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3464-3471.	3.0	19
75	Î²-Fluorofentanyl Are pH-Sensitive Mu Opioid Receptor Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1353-1356.	2.8	18
76	Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptorâ€™Ligand Interactions. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1019-1024.	2.8	17
77	Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7557-7574.	6.4	16
78	Rational Drug Design Leading to the Identification of a Potent 5-HT <sub>2C</sub> Agonist Lacking 5-HT <sub>2B</sub> Activity. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 929-932.	2.8	15
79	Defining Structureâ€™Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D <sub>1</sub> Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3753-3772.	6.4	15
80	Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4579-4602.	6.4	15
81	Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands. <i>Molecular Pharmacology</i> , 2007, 71, 759-768.	2.3	14
82	<i>trans</i> -2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and <i>trans</i> -2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT <sub>2</sub> receptor family. <i>Beilstein Journal of Organic Chemistry</i> , 2012, 8, 1705-1709.	2.2	14
83	Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. <i>JCI Insight</i> , 2017, 2, .	5.0	14
84	Aryl Biphenylâ€™methylpiperazines as 5-HT <sub>7</sub> Receptor Antagonists. <i>ChemMedChem</i> , 2013, 8, 1855-1864.	3.2	12
85	Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 1106-1127.	9.4	12
86	Differential Roles of Extracellular Histidine Residues of GPR68 for Proton-Sensing and Allosteric Modulation by Divalent Metal Ions. <i>Biochemistry</i> , 2020, 59, 3594-3614.	2.5	11
87	Chemical Modifications on 4-Arylpiperazine-Ethyl Carboxamide Derivatives Differentially Modulate Affinity for 5-HT1A, D4.2, and Î±2A Receptors: Synthesis and In Vitro Radioligand Binding Studies. <i>Australian Journal of Chemistry</i> , 2010, 63, 56.	0.9	10
88	Molecular interactions between general anesthetics and the 5HT <sub>2B</sub> receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2015, 33, 211-218.	3.5	10
89	N-Tetrahydrothiochromenoisoxazole-1-carboxamides as selective antagonists of cloned human 5-HT2B. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5488-5490.	2.2	8
90	Heterotropic Cooperativity within and between Protomers of an Oligomeric M <sub>2</sub> Muscarinic Receptor. <i>Biochemistry</i> , 2012, 51, 4518-4540.	2.5	8

#	ARTICLE	IF	CITATIONS
91	Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3671-3679.	3.0	3
92	Allostery of atypical modulators at oligomeric G protein-coupled receptors. <i>Scientific Reports</i> , 2021, 11, 9265.	3.3	2
93	Structural optimizations and bioevaluation of N-H aporphine analogues as Gq-biased and selective serotonin 5-HT <sub>2C</sub> receptor agonists. <i>Bioorganic Chemistry</i> , 2022, 123, 105795.	4.1	2
94	Design and development of selective muscarinic agonists for the treatment of alzheimer's disease: characterization of tetrahydropyrimidine derivatives and dev. <i>Pharmacochemistry Library</i> , 2000, , 135-140.	0.1	0
95	Investigation of the D <sub>1</sub> & D <sub>2</sub> dopamine receptor heteromer reveals a complex signaling mechanism not limited to G q protein activation. <i>FASEB Journal</i> , 2013, 27, 881.1.	0.5	0